Sales of Drugs From Multinational Corporations Will Represent 92 Percent of Mexico's Non-Small-Cell Lung Cancer Drug Market in 2014
Advertisement
Merck KGaA's Erbitux and Bayer's Nexavar Are Expected to Be Approved for Non-Small-Cell Lung Cancer in Mexico During the 2009 - 2014 Study Period, According to a New Report from Decision Resources